The most powerful person at the FDA isn’t always the commissioner—it’s whoever can make the next headline happen.
Quick Take
- Dr. Marty Makary resigned as FDA commissioner on May 13, 2026, after a short, conflict-heavy tenure.
- Two policy flashpoints—flavored e-cigarettes and mifepristone—helped turn internal tension into an exit.
- President Trump publicly posted Makary’s resignation text, an unusual show of control over the narrative.
- Kyle Diamantas stepped in as acting commissioner, leaving the agency in a familiar holding pattern.
A resignation that reads like a warning label
Dr. Marty Makary’s resignation landed like a dropped tray in a quiet cafeteria: loud, sudden, and revealing. The timeline matters because it shows how pressure works in Washington.
The FDA approved flavored e-cigarettes from Glas Inc. on May 6, 2026, after reported White House pressure; Makary then missed a White House maternal health event on May 12; he resigned May 13, and Kyle Diamantas became acting commissioner immediately. That sequence doesn’t prove motive by itself, but it does show momentum.
Makary’s public resignation message stayed polite—“honor of a lifetime,” “forever grateful”—and that’s exactly what makes it consequential. People don’t write those notes to explain policy; they write them to exit without lighting every bridge on fire.
Trump’s decision to post the text publicly did something else: it made the resignation less of a personal choice and more of a management decision performed in public, like a termination without the word.
Flavored vapes: the collision of markets, kids, and politics
Flavored e-cigarettes sit at the center of an American contradiction: adults demand choices and regulators worry about teenagers. The FDA has restricted flavored products because fruit and candy flavors can attract youth, while industry argues adult smokers use flavors to switch away from cigarettes.
When the administration pushed for approval of Glas Inc.’s fruit-flavored vapes, it created a simple test of independence: would the agency follow its historical caution or the White House’s direction?
US FDA Commissioner Marty Makary resigned, President Trump said, after weeks of clashing with top White House and health advisers and drawing scrutiny for a series of controversial decisions, according to several people familiar with internal dynamics https://t.co/NumUuKkfFJ pic.twitter.com/HhmdfGW1J9
— Reuters Health (@Reuters_Health) May 12, 2026
Makary reportedly resisted at first, citing public health concerns, then the approval arrived anyway. Readers should keep two truths in their head at once. First, presidents get to set policy direction; elections have consequences, and agencies are not sovereign nations.
Second, the FDA’s value comes from public trust that scientific review doesn’t change depending on who last walked through the Oval Office. When political leadership treats approvals like trophies, the regulator begins to look like a marketing department.
Mifepristone: a review that became a loyalty test
The mifepristone conflict ran on a longer fuse. In June 2025, HHS Secretary Robert F. Kennedy Jr. asked for a review of the drug’s safety and efficacy, framed around real-world outcomes.
By December 2025, reports said Makary had “slow-walked” the study, and conservative groups—including Susan B. Anthony Pro-Life America—called for his firing. That turns an internal scientific process into a public stopwatch: speed becomes the signal of alignment.
Common sense says reviews should move with urgency but not with panic. Americans often demand accountability from agencies, and that instinct is healthy; unelected bureaucracies can drift. The risk comes when “accountability” becomes indistinguishable from “deliver the outcome my side wants, on my timeline.”
The FDA’s job isn’t to perform politics with lab coats. It’s to evaluate evidence and document reasoning so the public can see how decisions were made—especially on issues as morally charged as abortion.
Inside the building: morale, micromanagement, and the press-release problem
Career FDA officials also criticized Makary’s management style, describing micromanaging and initiatives staff learned about through press releases rather than internal channels. Those complaints matter because an agency’s power isn’t only in its legal authority; it’s in its internal discipline.
When staff feel whiplash—new priorities, unclear processes, decisions announced externally first—good people either disengage or leave. That’s how capacity erodes even when the budget stays the same.
Makary came into the role with a public profile from the COVID era, when he criticized certain public health measures and became well-known beyond medical circles. That kind of visibility can help a commissioner communicate, but it can also tempt leaders to govern by microphone.
One unnamed official’s description of “endless self-promotion” is an allegation, not a verdict, yet it fits a pattern seen across administrations: communication strategy starts driving policy schedule.
What happens next when “acting” becomes the default setting
Kyle Diamantas taking over as acting commissioner keeps the trains running, but acting leadership also signals vulnerability. Industry watches for openings; advocacy groups press harder; staff wait to see what counts as “safe” disagreement.
Regulatory uncertainty doesn’t just slow approvals—it can speed the wrong ones, because teams try to guess what leadership wants and pre-comply. The public rarely sees that invisible pressure, but it’s often more influential than any single memo.
Trump called Makary “a terrific guy” and “a great doctor,” while acknowledging he “was having some difficulty.” That kind of praise-with-a-shrug is classic Washington distancing: compliment the résumé, erase the conflict, move on.
The bigger question isn’t whether Makary was right on every call. The bigger question is whether the FDA can keep credibility when commissioners become short-term fixtures and high-stakes decisions start looking like political deliverables instead of documented scientific judgments.
The open loop is unavoidable: the next permanent commissioner will inherit two live wires—vaping and mifepristone—and a staff that just watched a boss exit under pressure.
If the administration wants a more industry-friendly FDA, it can pursue that through transparent rulemaking and clear standards, not back-channel arm-twisting that leaves everyone guessing. Trust, once cracked, doesn’t reseal easily. The agency that decides what’s safe to swallow can’t afford to look like it’s swallowing orders.
Sources:
Marty Makary resigns as FDA commissioner after internal tensions.
FDA commissioner Marty Makary resigns, capping turbulent tenure
